We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PET imaging for tau visualization in the brain

PET imaging for tau visualization in the brain content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Tau is an excellent biomarker and a major pharmaceutic target for Alzheimer’s disease (AD) given its contribution to neurodegeneration.

Aberrant accumulation and aggregation of phosphorylated Tau (p-Tau), and formation of neurofibrillary tangles (NFT) composed of hyperphosphorylated Tau, are a prominent characteristic of AD. Tau pathology has been linked to both sporadic and familial forms of AD; with over 40 different mutations found in the gene that encodes this protein [microtubule-associated protein tau (MAPT) gene].

The use of imaging agents that can efficiently cross the blood-brain barrier (BBB) and detect pathological forms of Tau with high specificity will allow specific monitoring of Tau species, and elucidating their temporal expression, topographical distribution and spatial relationship relative to disease pathology and clinical changes that occur during disease progression.

Non-invasive assessment of Tau deposition and correlation with the extent of neurodegeneration will provide new insights into tau pathology in the human brain.

Refer to BioLegend’s Tau homepage to learn more about Tau protein and a comprehensive list of Tau antibodies and recombinant proteins